Showing 3531-3540 of 7035 results for "".
- Imagining a Better Future for Hidradenitis Suppurativahttps://practicaldermatology.com/news/imagining-a-better-future-for-hidradenitis-suppurativa/2485556/Hidradenitis suppurativa (HS) has long been misunderstood, underdiagnosed, and undertreated. However, at a recent panel discussion led by Vivian Shi, MD, at
- Povorcitinib Improves Lesion Burden and Pain in Hidradenitis Suppurativahttps://practicaldermatology.com/news/povorcitinib-improves-lesion-burden-and-pain-in-hidradenitis-suppurativa/2485551/Oral povorcitinib produced early and sustained improvements in lesion burden and pain in patients with moderate-to-severe hidradenitis suppurativa (HS), according to “Effect of Povorcitinib on Hidradenitis Suppurativa Lesions Through 24 Weeks in STOP-HS Trials,” a poster by Jennifer L. Hsiao, MD,
- Drs. Neal Bhatia and Ted Rosen Present New Therapeutics ‘Popping’ in 2026https://practicaldermatology.com/news/drs-neal-bhatia-and-ted-rosen-present-new-therapeutics-popping-in-2026/2485511/In their annual overview of therapeutics at Maui Derm Hawaii 2026, Ted Rosen, MD, and Neal Bhatia, MD, used a K-Pop Demon Hunters theme to walk through emerging strategies across inflammatory skin diseases. Drs. Rosen and Bhatia emphasized a shift toward non‑steroidal topicals that can be
- New Data Show BMI Influences Psoriasis Severity and Systemic Inflammationhttps://practicaldermatology.com/news/new-data-show-bmi-influences-psoriasis-severity-and-systemic-inflammation/2485411/Obesity and overweight status were associated with higher baseline prevalence of cardiometabolic comorbidities, psoriatic arthritis (PsA), and systemic inflammation compared to individuals with normal BMI, according to new data from a poster at 2026 Winter Clinical
- Dr. Amy McMichael Highlights Breakthrough Alopecia Therapieshttps://practicaldermatology.com/news/dr-amy-mcmichael-highlights-breakthrough-alopecia-therapies/2485364/Anyone not using low-dose oral minoxidil yet has “missed the boat.” That was the message from Amy McMichael, MD, during her presentation on non-scarring hair loss at the 2026 Winter Clinical Dermatology Conference in Hawaii. Dr. McMichael, who before her presentation was named the conferen
- Analysis: CHL-Fe-based PDT Shows Activity Against Drug-Resistant C. acneshttps://practicaldermatology.com/news/chl-febased-photodynamic-therapy-shows-potent-activity-against-drug-resistant-c-acnes/2485327/Photodynamic therapy (PDT) using sodium iron chlorophyllin (CHL-Fe) and red light achieved consistent bactericidal effects against drug-resistant Cutibacterium acnes (C. acnes) strains in vitro, according to new study finding
- Study: Gut Permeability Biomarker Linked with AD Symptom Reliefhttps://practicaldermatology.com/news/study-gut-permeability-biomarker-linked-with-ad-symptom-relief/2485110/New research suggests serum D-lactate levels may predict clinical response to washed microbiota transplantation (WMT), showing the role of intestinal barrier dysfunction in atopic dermatitis (AD). Researchers for the prospective
- Study Links BMI and IBD Causally to Hidradenitis Suppurativahttps://practicaldermatology.com/news/mendelian-randomization-study-links-bmi-and-ibd-causally-to-hidradenitis-suppurativa/2485068/A new mendelian randomization (MR) analysis provides genetic evidence supporting a causal role for elevated body mass index (BMI) and inflammatory bowel disease (IBD) in hidradenitis suppurativa (HS). Study researchers used gen
- Most Insurers Cover Botulinum Toxin for Axillary Hyperhidrosis: Analysishttps://practicaldermatology.com/news/most-insurers-cover-botulinum-toxin-for-axillary-hyperhidrosis-analysis/2484933/A new cross-sectional study published in the Journal of Drugs in Dermatology finds that while botulinum toxin is broadly covered by private insurers for the treatment of primary axillary hyperhidrosis, access barriers due to
- Systematic Review Shows BTX Effective for Ischemic Digital Complicationshttps://practicaldermatology.com/news/systematic-review-btx-effective-for-ischemic-digital-complications/2484841/Botulinum toxin (BTX) injections may offer a promising rescue therapy for patients with refractory digital ischemia, ulcers, or gangrene associated with systemic sclerosis and other vasculopathies, according to findings from a systematic review in